Investors in Fractyl Health, Inc. Urged to Seek Legal Counsel Following Stock Drop

Investor Action Notice: A Call to Fractyl Health Investors

On January 29, 2026, Fractyl Health, Inc. found itself in the midst of controversy after announcing preliminary data from its REMAIN-1 Midpoint Cohort study. This investigation focuses on whether the company had properly communicated crucial information that could impact its stock value.

Key Developments

Fractyl Health, a company listed under NASDAQ with the ticker symbol GUTS, published data indicating that patients treated with Revita for weight maintenance after GLP-1 therapy faced a 4.5% weight regain, a concerning figure when compared to the 7.5% regain of those receiving a sham treatment. This announcement occurred before stock markets opened, affecting the company's share price immediately following the news.

During an investor call held on the same day, management disclosed alarming information about one study site reporting significantly higher weight regain across treatment groups, which heavily influenced the results. Following this news, Fractyl's stock price plummeted by $1.245 per share, marking a staggering 68.03% decrease, resulting in a closing price of $0.585.

In a subsequent report, Canaccord Genuity suggested that this weight regain variance stemmed from a less effective diet and lifestyle counseling program at that study site. These revelations prompted a downgrade from Morgan Stanley, decreasing the price target for Fractyl stock from $8.00 to $2.00. The next trading day saw the stock fall an additional 21.37%, closing at $0.46 per share on January 30.

Investors’ Rights and Legal Options

In the wake of such sharp declines in stock value, Moore Law PLLC is stepping in to assist affected shareholders. The law firm encourages investors who own securities of Fractyl Health, Inc. to reach out and discuss potential legal actions. The repercussions of the recent investigations could include monetary damages, corporate governance reforms, and reimbursement to the company.

Fletcher Moore, a representative from the firm, stated that there are no upfront costs for investors seeking representation. All legal efforts will operate on a contingency fee basis, meaning shareholders will not bear any financial burden unless a settlement is reached.

The details surrounding the REMAIN-1 cohort indicate a potential gap in the company's communication regarding study outcomes and the variables affecting them. Investors who feel they have been misled have a path towards seeking justice through legal channels.

How to Reach Out

If you are one of the investors impacted by these developments, Moore Law is urging you to contact them immediately at [email protected]. You might still have the opportunity to take part in the legal process, reinforcing your rights as a shareholder. The law firm is located at 30 Wall Street, 8th Floor, New York, NY 10005, reachable for consultations and to handle inquiries.

The stock market is a realm where information is key, and actions taken during flashes of news can greatly impact value. Investors are encouraged to stay informed and connected with legal resources, especially in times of uncertainty.

As this situation unfolds, it remains crucial for stakeholders of Fractyl Health to remain vigilant about their investments. Regular updates and legal insights will be vital in navigating the aftermath of this stock drop. Stay connected, and do not hesitate to reach out if you need guidance during this tumultuous period.